Search
Selected Filters
Displaying 21–30 of 385 news results
-
Opus Genetics Launches Gene Therapy Clinical Trial for Best Disease
Research NewsThe Foundation funded preclinical studies for the approach and launched Opus.
-
SparingVision Launches Clinical Trial for Therapy to Re-Activate Dormant Cones in Advanced RP
Research NewsThe approach may provide better visual acuity than current optogenetic therapies in clinical trials.
-
Annual Funded Grants – CRISPR and Prime Editing Technologies
Research NewsFunded grants for CRISPR and prime editing approaches.
-
Sepul Bio’s LCA10 RNA Therapy Moves into Phase 3 Clinical Trial
Research NewsThe emerging therapy improved vision for some participants in an earlier clinical trial.
-
Research News
Durable vision improvements were also observed out to 18 months for previously dosed adult patients in the trial.
-
Foundation Fighting Blindness Announces Over $9 Million in New Research Awards for FY2025
Research NewsThe Foundation Fighting Blindness is proud to announce the funding of 16 innovative research projects in Fiscal Year 2025, totaling over $9 million in new grants.
-
Letter to House Energy & Commerce Committee regarding H.R.1262, the Give Kids a Chance Act.
Advocacy Research NewsOn behalf of the Foundation Fighting Blindness and the millions of Americans impacted by inherited retinal diseases (IRDs), we urge you to advance H.R.1262, the Give Kids a Chance Act, and reauthorize the Rare Pediatric Disease Priority Review Voucher (PRV) Program.
-
Nacuity’s Antioxidative Therapy NACA Performs Encouragingly in Phase 1/2 Clinical Trial
Research NewsNACA is a gene-agnostic, oral medication designed to preserve vision in people with retinitis pigmentosa and Usher syndrome.
-
Opus Genetics Receives FDA Clearance to Launch Clinical Trial for Best1 Gene Therapy
Research NewsThe Foundation funded earlier, proof-of-concept studies for the Best1 gene therapy and later launched Opus to develop several IRD gene therapies.
-
jCyte Launches New Phase 2 Clinical Trial for its Cell-Based RP Therapy
Research NewsThe trial is evaluating a cell dose that is 50 percent higher than the highest dose used in a previous Phase 2b trial.
.png)
